This is a numbers-first look at Suven Life Sciences Limited (SUVEN), covering income trends, margins, valuation, and shareholding.
Suven Life Revenue Trend
Top-line pressure showed for Suven Life Sciences Limited, with revenue declining 43.1% to ₹6.66 Cr in FY2025.
The 10-year revenue trajectory tells a worrying story: a 35.3% annual decline from ₹521 Cr to ₹6.66 Cr.
A ₹6.66 Cr revenue base makes Suven Life Sciences Limited a smaller name in the Indian pharmaceuticals sector.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹6.66 Cr | -43.1% |
| FY2024 | ₹11.7 Cr | -13.6% |
| FY2023 | ₹13.5 Cr | +14.3% |
| FY2022 | ₹11.8 Cr | -44.2% |
| FY2021 | ₹21.2 Cr | — |
View Suven Life Sciences Limited's full 10-year revenue trend with CAGR analysis →
Suven Life Profitability
Per-share earnings moved to ₹-7.37 in FY2025 from ₹-4.82 in FY2024.
Is Suven Life Undervalued
The P/E Ratio approach puts Suven Life Sciences Limited's intrinsic value at ****, a % from the current market price.
Suven Life Sciences Limited shares are currently trading at ₹275.35.
Craytheon also calculates intrinsic value using the EPS Growth model. The full breakdown with assumptions is available in the detailed analysis.
See all valuation models for Suven Life Sciences Limited with detailed assumptions →
Suven Life Shareholding Pattern
A stable promoter holding of 70.2% over 4 quarters suggests the management group is comfortable with its position.
Foreign institutions moved their stake up to 0.9% from 0.6% over the past year.
On the domestic institutional side, the holding is 4.6% as of March 2026 — up from 0.0%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 70.2% | 0.9% | 4.6% | 24.3% |
| Dec 2025 | 67.4% | 1.1% | 3.4% | 28.2% |
| Sep 2025 | 67.4% | 1.2% | 3.4% | 28.1% |
| Jun 2025 | 70.3% | 0.6% | 0.0% | 29.1% |
Track quarterly shareholding changes for Suven Life Sciences Limited →
Suven Life Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹1.35B at the end of FY2025, down 52.6% from ₹2.85B a year earlier.
Property, Plant & Equipment is the largest block at 44.0%, followed by Cash & ST Investments at 27.6% and Other Assets at 27.1%.
Equity makes up 81.4% of liabilities and equity, with debt at 0.0% and operating liabilities at 18.6%. Notable shift: Other Liabilities is up 65.3% YoY (₹120.84M → ₹199.70M).
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 373.04M |
| Receivables | 13.36M |
| Inventories | 2.38M |
| Property, Plant & Equipment | 594.82M |
| Intangibles & Goodwill | 1.81M |
| Other Assets | 366.43M |
| Category | Value |
|---|---|
| Equity | 1.10B |
| Trade Payables | 52.27M |
| Other Liabilities | 199.70M |
Suven Life Key Highlights
In summary, Suven Life Sciences Limited (SUVEN) presents the following picture for fundamental analysts.
Revenue of ₹6.66 Cr in FY2025, down 43.1% year-over-year.
Long-term revenue has been contracting at 35.3% annually over 10 years.
The company reported a net loss of ₹161 Cr in FY2025.
Unlock Full Analysis
Craytheon's full analysis of Suven Life Sciences Limited goes deeper: three valuation models, growth metrics, and 10 years of financial data.